Featured Studies Results

Cancer: Breast | Study Type: Treatment

A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer identifier:
NCT05720039 (

Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer

Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation identifier:
NCT04673448 (

Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer identifier:
NCT02693535 (

Cancer treatment study for people with advanced solid tumors

Comparing the Safety and Effectiveness of a New Hormonal Therapy in Patients with HER2-Negative, ER-Positive Early Breast Cancer identifier:
NCT04961996 (

Treatment study for people with early-stage breast cancer

Testing the Targeted Therapy Elimusertib in Combination with Chemotherapy for Advanced Cancers identifier:
NCT04491942 (

Treatment study for people with advanced cancers

PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO) identifier:
NCT05169437 (

Any advanced or metastatic solid tumor except ovarian or prostate

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib identifier:
NCT04550494 (

Treatment study for people with advanced solid tumors

Study of Two Drugs in ER+ and/or PR+ Cancers With PI3K and/or PTEN Tumor or Inherited Mutations identifier:
NCT05082025 (

People with advanced breast or endometrial or ovarian cancer

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors identifier:
NCT05252390 (

Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells identifier:
NCT04150042 (

Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation

Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation identifier:
NCT04584255 (

Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA) identifier:
NCT04644068 (

Advanced ovarian, breast, prostate or pancreatic cancer

Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study) identifier:
NCT04497116 (

Advanced solid tumors

ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer identifier:
NCT04267939 (

Advanced ovarian cancer or other solid tumors

A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors identifier:
NCT04991480 (

Advanced solid tumors

Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors identifier:
NCT04657068 (

Advanced solid tumors

Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations identifier:
NCT04586335 (

Advanced solid tumors

HOPE: Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer identifier:
NCT03685331 (


A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded) identifier:
NCT03344965 (


Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations identifier:
NCT03990896 (


A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients identifier:
NCT04353973 (


Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial identifier:
NCT02603341 (



FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.